Compare NBXG & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBXG | OPK |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 1995 |
| Metric | NBXG | OPK |
|---|---|---|
| Price | $13.93 | $1.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.28 |
| AVG Volume (30 Days) | 243.7K | ★ 3.1M |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $642,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.31 | $1.11 |
| 52 Week High | $12.23 | $2.04 |
| Indicator | NBXG | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 33.48 | 43.71 |
| Support Level | $14.67 | $1.28 |
| Resistance Level | $14.69 | $1.42 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 5.69 | 25.16 |
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.